Rhinostics

Executive Summary

Rhinostics is a diagnostics company specializing in infectious disease testing, with a strategic focus on respiratory sample collection and analysis. The company has developed proprietary technologies aimed at improving the accuracy and speed of diagnostic testing, addressing critical needs in both clinical and sports performance settings. While the company's description mentions a sports performance lab, its core competencies align with cutting-edge diagnostic solutions, leveraging science and technology to enhance disease detection and athlete health monitoring. Founded in 2018 and headquartered in St. Louis, Missouri, Rhinostics operates in the high-growth diagnostics sector, which has seen increased demand due to ongoing public health priorities. Although the company has limited public financial or operational data, its positioning in the infectious disease space suggests it could benefit from regulatory milestones and strategic partnerships. As a private company, Rhinostics may pursue FDA clearances for its diagnostic platforms or expand into new markets, potentially driving near-term value.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for novel respiratory sample collection device60% success
• TBDCommercial partnership with major sports organization or clinical lab50% success
• Q4 2026Launch of expanded infectious disease testing panel45% success